# Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

> **NCT01934335** · PHASE2 · TERMINATED · sponsor: **Ronald Weigel** · enrollment: 12 (actual)

## Conditions studied

- Invasive Breast Cancer

## Interventions

- **DRUG:** Vandetanib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01934335
- **Lead sponsor:** Ronald Weigel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2018-12-21
- **Final completion:** 2018-12-21
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Drugs unavailable
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934335, "Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01934335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*